Boehringer Ingelheim Biopharmaceuticals China Ltd

Registered sites: 3
Drug products: 127
Live patents: 547
Countries: 2
Base: Germany

Authorisation

Registered operations

What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.

Analytical testingActive ingredient (API) manufactureLabellingFinished drug manufacturePackaging

Sites

Facilities

Site	Location	Operations	FEI
Boehringer Ingelheim Biopharmaceuticals (China) Ltd. (Branch Plant)	ShanghaiChina	Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging	3015009021
Boehringer Ingelheim Pharma GmbH and Co. KG	Biberach an der RissGermany	Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging	3002806518
Boehringer Ingelheim Pharma GmbH and Co. KG	Ingelheim am RheinGermany	Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging	3002806556

Exclusivity

Patents

547

Unexpired Orange Book patents where this company is the application holder.

Product	Active ingredient	Expiry
GILOTRIF	AFATINIB DIMALEATE	Nov 2026
GILOTRIF	AFATINIB DIMALEATE	May 2027
GILOTRIF	AFATINIB DIMALEATE	Oct 2029
GILOTRIF	AFATINIB DIMALEATE	Dec 2029
GILOTRIF	AFATINIB DIMALEATE	Apr 2030
GILOTRIF	AFATINIB DIMALEATE	Jun 2030
GILOTRIF	AFATINIB DIMALEATE	Jul 2030
GILOTRIF	AFATINIB DIMALEATE	Jan 2031
GLYXAMBI	EMPAGLIFLOZIN; LINAGLIPTIN	Apr 2027
GLYXAMBI	EMPAGLIFLOZIN; LINAGLIPTIN	May 2027
GLYXAMBI	EMPAGLIFLOZIN; LINAGLIPTIN	Oct 2027
GLYXAMBI	EMPAGLIFLOZIN; LINAGLIPTIN	Nov 2027
GLYXAMBI	EMPAGLIFLOZIN; LINAGLIPTIN	Aug 2028
GLYXAMBI	EMPAGLIFLOZIN; LINAGLIPTIN	Feb 2029
GLYXAMBI	EMPAGLIFLOZIN; LINAGLIPTIN	Oct 2029
GLYXAMBI	EMPAGLIFLOZIN; LINAGLIPTIN	Feb 2030
GLYXAMBI	EMPAGLIFLOZIN; LINAGLIPTIN	Apr 2030
GLYXAMBI	EMPAGLIFLOZIN; LINAGLIPTIN	Aug 2030
GLYXAMBI	EMPAGLIFLOZIN; LINAGLIPTIN	Apr 2034
GLYXAMBI	EMPAGLIFLOZIN; LINAGLIPTIN	Jun 2034
GLYXAMBI	EMPAGLIFLOZIN; LINAGLIPTIN	Oct 2034
GLYXAMBI	EMPAGLIFLOZIN; LINAGLIPTIN	Jun 2037
GLYXAMBI	EMPAGLIFLOZIN; LINAGLIPTIN	Dec 2037
HERNEXEOS	ZONGERTINIB	Nov 2026
HERNEXEOS	ZONGERTINIB	Jul 2041
JARDIANCE	EMPAGLIFLOZIN	Apr 2027
JARDIANCE	EMPAGLIFLOZIN	Oct 2027
JARDIANCE	EMPAGLIFLOZIN	Aug 2028
JARDIANCE	EMPAGLIFLOZIN	Feb 2029
JARDIANCE	EMPAGLIFLOZIN	Oct 2029
JARDIANCE	EMPAGLIFLOZIN	Feb 2030
JARDIANCE	EMPAGLIFLOZIN	Apr 2030
JARDIANCE	EMPAGLIFLOZIN	Aug 2030
JARDIANCE	EMPAGLIFLOZIN	Apr 2033
JARDIANCE	EMPAGLIFLOZIN	Oct 2033
JARDIANCE	EMPAGLIFLOZIN	Apr 2034
JARDIANCE	EMPAGLIFLOZIN	May 2034
JARDIANCE	EMPAGLIFLOZIN	Jun 2034
JARDIANCE	EMPAGLIFLOZIN	Oct 2034
JARDIANCE	EMPAGLIFLOZIN	Nov 2034
JARDIANCE	EMPAGLIFLOZIN	Dec 2034
JASCAYD	NERANDOMILAST	Nov 2029
JASCAYD	NERANDOMILAST	Aug 2032
JASCAYD	NERANDOMILAST	Feb 2034
JASCAYD	NERANDOMILAST	Oct 2038
JENTADUETO	LINAGLIPTIN; METFORMIN HYDROCHLORIDE	Nov 2027
JENTADUETO	LINAGLIPTIN; METFORMIN HYDROCHLORIDE	Apr 2029
JENTADUETO	LINAGLIPTIN; METFORMIN HYDROCHLORIDE	Oct 2029
JENTADUETO	LINAGLIPTIN; METFORMIN HYDROCHLORIDE	Apr 2030
JENTADUETO	LINAGLIPTIN; METFORMIN HYDROCHLORIDE	May 2030
JENTADUETO	LINAGLIPTIN; METFORMIN HYDROCHLORIDE	Jun 2030
JENTADUETO	LINAGLIPTIN; METFORMIN HYDROCHLORIDE	Nov 2030
JENTADUETO	LINAGLIPTIN; METFORMIN HYDROCHLORIDE	Dec 2030
JENTADUETO	LINAGLIPTIN; METFORMIN HYDROCHLORIDE	Jun 2037
JENTADUETO	LINAGLIPTIN; METFORMIN HYDROCHLORIDE	Dec 2037
JENTADUETO XR	LINAGLIPTIN; METFORMIN HYDROCHLORIDE	Nov 2027
JENTADUETO XR	LINAGLIPTIN; METFORMIN HYDROCHLORIDE	Apr 2029
JENTADUETO XR	LINAGLIPTIN; METFORMIN HYDROCHLORIDE	Oct 2029
JENTADUETO XR	LINAGLIPTIN; METFORMIN HYDROCHLORIDE	Apr 2030
JENTADUETO XR	LINAGLIPTIN; METFORMIN HYDROCHLORIDE	May 2030

Catalogue

Marketed products

127

Showing 127 of 127.

Brand	Generic name	Form	Category
Adalimumab-adbm	Adalimumab-adbm	KIT	BLA
Adalimumab-adbm	Adalimumab-adbm	KIT	BLA
Adalimumab-adbm	Adalimumab-adbm	KIT	BLA
Adalimumab-adbm	Adalimumab-adbm	KIT	BLA
Adalimumab-adbm	Adalimumab-adbm	KIT	BLA
Adalimumab-adbm	Adalimumab-adbm	KIT	BLA
-	Aldesleukin	POWDER	DRUG FOR FURTHER PROCESSING
-	Alemtuzumab	SOLUTION	DRUG FOR FURTHER PROCESSING
-	Alemtuzumab	SOLUTION	BULK INGREDIENT
-	Alemtuzumab	SOLUTION	DRUG FOR FURTHER PROCESSING
-	Alemtuzumab	SOLUTION	BULK INGREDIENT
-	Alteplase	SOLUTION	BULK INGREDIENT
-	Alteplase	POWDER	DRUG FOR FURTHER PROCESSING
-	Alteplase	POWDER	DRUG FOR FURTHER PROCESSING
-	Atropine	POWDER	BULK INGREDIENT
-	Atropine Sulfate	POWDER	BULK INGREDIENT
Atrovent HFA	ipratropium bromide	AEROSOL, METERED	NDA
-	BUTYLSCOPOLAMINE BROMIDE	POWDER	BULK INGREDIENT
Combivent Respimat	ipratropium bromide and albuterol	SPRAY, METERED	NDA
Cyltezo	adalimumab-adbm	KIT	BLA
Cyltezo	adalimumab-adbm	KIT	BLA
Cyltezo	adalimumab-adbm	KIT	BLA
Cyltezo	adalimumab-adbm	KIT	BLA
Cyltezo	adalimumab-adbm	KIT	BLA
Cyltezo	adalimumab-adbm	KIT	BLA
-	Durvalumab	SOLUTION	BULK INGREDIENT
-	Empagliflozin	POWDER	BULK INGREDIENT
Gilotrif	afatinib	TABLET, FILM COATED	NDA
Gilotrif	afatinib	TABLET, FILM COATED	NDA
Gilotrif	afatinib	TABLET, FILM COATED	NDA
Glyxambi	empagliflozin and linagliptin	TABLET, FILM COATED	NDA
Glyxambi	empagliflozin and linagliptin	TABLET, FILM COATED	NDA
HERNEXEOS	zongertinib	TABLET, FILM COATED	NDA
-	Infliximab	SOLUTION	BULK INGREDIENT
-	Interferon beta-1b	POWDER	DRUG FOR FURTHER PROCESSING
-	Interferon-gamma1b	SOLUTION	DRUG FOR FURTHER PROCESSING
JASCAYD	nerandomilast	TABLET, FILM COATED	NDA
JASCAYD	nerandomilast	TABLET, FILM COATED	NDA
Jardiance	Empagliflozin	TABLET, FILM COATED	NDA
Jardiance	Empagliflozin	TABLET, FILM COATED	NDA
-	Jardiance	POWDER	DRUG FOR FURTHER PROCESSING
-	Jardiance	POWDER	DRUG FOR FURTHER PROCESSING
Jentadueto	linagliptin and metformin hydrochloride	TABLET, FILM COATED	NDA
Jentadueto	linagliptin and metformin hydrochloride	TABLET, FILM COATED	NDA
Jentadueto	linagliptin and metformin hydrochloride	TABLET, FILM COATED	NDA
Jentadueto XR	linagliptin and metformin hydrochloride	TABLET, FILM COATED, EXTENDED RELEASE	NDA
Jentadueto XR	linagliptin and metformin hydrochloride	TABLET, FILM COATED, EXTENDED RELEASE	NDA
Micardis HCT	telmisartan and hydrochlorothiazide	TABLET	NDA
Micardis HCT	telmisartan and hydrochlorothiazide	TABLET	NDA
Micardis HCT	telmisartan and hydrochlorothiazide	TABLET	NDA
-	Nerandomilast	POWDER	BULK INGREDIENT
Ofev	nintedanib	CAPSULE	NDA
Ofev	nintedanib	CAPSULE	NDA
-	PHENYLEPHRINE HYDROCHLORIDE	POWDER	BULK INGREDIENT
-	Palivizumab	SOLUTION	DRUG FOR FURTHER PROCESSING
-	Palivizumab	SOLUTION	DRUG FOR FURTHER PROCESSING
-	Pembrolizumab	SOLUTION	DRUG FOR FURTHER PROCESSING
-	Pembrolizumab	LIQUID	DRUG FOR FURTHER PROCESSING
Pradaxa	dabigatran etexilate mesylate	CAPSULE	NDA
Pradaxa	dabigatran etexilate mesylate	CAPSULE	NDA
Pradaxa	dabigatran etexilate mesylate	CAPSULE	NDA
Pradaxa	dabigatran etexilate	PELLET	NDA
Pradaxa	dabigatran etexilate	PELLET	NDA
Pradaxa	dabigatran etexilate	PELLET	NDA
Pradaxa	dabigatran etexilate	PELLET	NDA
Pradaxa	dabigatran etexilate	PELLET	NDA
Pradaxa	dabigatran etexilate	PELLET	NDA
Praxbind	idarucizumab	INJECTION	BLA
-	Risankizumbab	LIQUID	BULK INGREDIENT
-	Risankizumbab	LIQUID	BULK INGREDIENT
-	Risankizumbab	SOLUTION	DRUG FOR FURTHER PROCESSING
-	Rituximab	SOLUTION	BULK INGREDIENT
SPEVIGO	spesolimab-sbzo	INJECTION	BLA
SPEVIGO	spesolimab-sbzo	INJECTION	BLA
SPEVIGO	spesolimab-sbzo	INJECTION	BLA
Spiriva HandiHaler	TIOTROPIUM BROMIDE	CAPSULE	NDA
Spiriva Respimat	tiotropium bromide inhalation spray	SPRAY, METERED	NDA
Spiriva Respimat	tiotropium bromide inhalation spray	SPRAY, METERED	NDA
Stiolto Respimat	tiotropium bromide and olodaterol	SPRAY, METERED	NDA
Striverdi Respimat	olodaterol respimat inhalation spray	SPRAY, METERED	NDA
Synjardy	empagliflozin and metformin hydrochloride	TABLET	NDA
Synjardy	empagliflozin and metformin hydrochloride	TABLET	NDA
Synjardy	empagliflozin and metformin hydrochloride	TABLET	NDA
Synjardy	empagliflozin and metformin hydrochloride	TABLET	NDA
-	Synjardy	TABLET	DRUG FOR FURTHER PROCESSING
-	Synjardy	TABLET	DRUG FOR FURTHER PROCESSING
-	Synjardy	TABLET	DRUG FOR FURTHER PROCESSING
-	Synjardy	TABLET	DRUG FOR FURTHER PROCESSING
Synjardy XR	empagliflozin, metformin hydrochloride	TABLET, EXTENDED RELEASE	NDA
Synjardy XR	empagliflozin, metformin hydrochloride	TABLET, EXTENDED RELEASE	NDA
Synjardy XR	empagliflozin, metformin hydrochloride	TABLET, EXTENDED RELEASE	NDA
Synjardy XR	empagliflozin, metformin hydrochloride	TABLET, EXTENDED RELEASE	NDA
-	Tafasitamab	POWDER	DRUG FOR FURTHER PROCESSING
-	Telmisartan	GRANULE	DRUG FOR FURTHER PROCESSING
-	Tenecteplase	SOLUTION	BULK INGREDIENT
-	Tenecteplase	POWDER, FOR SOLUTION	DRUG FOR FURTHER PROCESSING
-	Tenecteplase	POWDER, FOR SOLUTION	DRUG FOR FURTHER PROCESSING
-	Tipranavir	POWDER	BULK INGREDIENT
Tradjenta	linagliptin	TABLET, FILM COATED	NDA
-	Tremelimumab	SOLUTION	BULK INGREDIENT
Trijardy XR	empagliflozin, linagliptin, metformin hydrochloride	TABLET, EXTENDED RELEASE	NDA
Trijardy XR	empagliflozin, linagliptin, metformin hydrochloride	TABLET, EXTENDED RELEASE	NDA
Trijardy XR	empagliflozin, linagliptin, metformin hydrochloride	TABLET, EXTENDED RELEASE	NDA
Trijardy XR	empagliflozin, linagliptin, metformin hydrochloride	TABLET, EXTENDED RELEASE	NDA
-	Zongertinib	TABLET	DRUG FOR FURTHER PROCESSING
-	Zongertinib	POWDER	BULK INGREDIENT
-	dabigatran etexilate	POWDER	BULK INGREDIENT
-	dabigatran etexilate	PELLET	DRUG FOR FURTHER PROCESSING
-	idarucizumab	LIQUID	BULK INGREDIENT
-	idarucizumab	LIQUID	DRUG FOR FURTHER PROCESSING
-	ipratropium bromide	POWDER	BULK INGREDIENT
-	linagliptin	POWDER	BULK INGREDIENT
-	linagliptin and metformin hydrochloride	TABLET	DRUG FOR FURTHER PROCESSING
-	linagliptin and metformin hydrochloride	TABLET	DRUG FOR FURTHER PROCESSING
-	nerandomilast	TABLET	DRUG FOR FURTHER PROCESSING
-	nerandomilast	TABLET	DRUG FOR FURTHER PROCESSING
-	nintedanib esilate	POWDER	BULK INGREDIENT
-	olodaterol	POWDER	BULK INGREDIENT
-	palivizumab	SOLUTION	BULK INGREDIENT
-	spesolimab	LIQUID	BULK INGREDIENT
-	tafasitamab	SOLUTION	BULK INGREDIENT
-	telmisartan	TABLET	DRUG FOR FURTHER PROCESSING
-	telmisartan	TABLET	DRUG FOR FURTHER PROCESSING
-	tiotropium bromide	POWDER	BULK INGREDIENT
-	tislelizumab	LIQUID	BULK INGREDIENT
-	tislelizumab	LIQUID	DRUG FOR FURTHER PROCESSING
-	trastuzumab	SOLUTION	BULK INGREDIENT

Provenance

Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.